Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03852511 |
| Title | First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE) |
| Acronym | FORTITUDE |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | PsiOxus Therapeutics Ltd |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of California, Los Angeles (UCLA) | Santa Monica | California | 90404 | United States | Details | |
| University of Colorado | Aurora | Colorado | 80045 | United States | Details | |
| Memorial Sloan Kettering Cancer Center (MSKCC) | New York | New York | 10038 | United States | Details | |
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States | Details | |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | United States | Details |